CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026

$300.02−0.13 (-0.04%)

Close on Oct 19, 2026

Market cap: $14.41B
P/E (TTM): –
Dividend yield: –

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-27	FY 2024 2024-12-28	FY 2023 2023-12-30	FY 2022 2022-12-31	FY 2021 2021-12-25	FY 2020 2020-12-26	FY 2019 2019-12-28	FY 2018 2018-12-29	FY 2017 2017-12-30	FY 2016 2016-12-31	FY 2015 2015-12-26	FY 2014 2014-12-27	FY 2013 2013-12-28	FY 2012 2012-12-29	FY 2011 2011-12-31	FY 2010 2010-12-25	FY 2009 2009-12-26	FY 2008 2008-12-27
Revenue	4,015	4,050	4,129	3,976	3,540	2,924	2,621	2,266	1,858	1,681	1,363	1,298	1,166	1,130	1,143	1,133	1,172	1,295
Cost of Revenue	–	–	–	–	–	–	–	–	290	277	264	266	273	258	268	253	256	253
Gross Profit	–	–	–	–	–	–	–	–	1,568	1,404	1,099	1,031	893	872	875	880	916	1,042
Selling, General & Admin	743	751	748	665	620	529	518	444	371	365	300	269	226	208	199	232	228	224
Advertising Expenses	–	–	–	–	–	–	–	1.90	1.60	1.40	1.20	1.30	1.10	0.90	–	–	–	–
Operating Income	25	227	617	651	590	433	351	331	288	238	206	178	151	166	174	-299	170	-452
Interest Expense	107	126	137	59	74	86	61	64	30	28	15	12	21	33	43	35	22	22
Interest & Investment Income	4.94	8.58	5.20	0.78	0.65	0.83	1.52	0.81	0.69	1.31	1.04	1.15	0.73	0.59	1.35	1.19	1.71	7.88
Income from Equity Investments	–	–	–	–	–	–	–	–	–	–	3.82	9.30	5.86	-0.62	–	–	–	–
Other Non-Operating Income	-23	-17	96	31	-36	100	12	13	38	12	3.01	11	7.17	-3.27	-0.41	-1.48	1.91	-5.15
Merger & Restructuring Charges	100	107	30	8.21	6.86	13	14	9.55	4.78	18	8.01	7.79	3.22	2.58	5.46	–	–	–
Asset Impairment Charges	165	215	0	0	0	0	0	0	17	6.72	0.20	2.20	3.80	3.50	7.49	91	0	700
Gain (Loss) on Sale of Assets	3.38	-0.66	-0.96	123	25	0	0	0	11	0	0	–	–	–	–	–	–	–
Pretax Income	-100	93	581	623	481	447	304	282	297	223	195	178	138	130	133	-334	152	-471
Income Tax Expense	43	68	101	130	82	82	50	54	171	67	43	48	33	28	17	0.02	40	57
Income from Continuing Operations	–	–	–	–	–	365	254	227	126	156	152	130	104	102	115	-329	113	-528
Income from Discontinued Operations	–	–	–	–	–	0	0	1.51	-0.14	0.28	-0.95	-1.73	-1.27	-4.25	-5.55	-8.01	1.40	3.28
Net Income incl. Noncontrolling Interests	-142	25	480	493	399	365	254	229	125	156	151	128	104	98	110	-342	113	-525
Minority Interest in Earnings	2.18	3.09	5.75	6.38	7.86	1.00	2.04	2.35	2.09	1.60	1.77	1.50	1.32	0.57	0.41	-5.45	-1.84	-0.69
Net Income	-144	22	475	486	391	364	252	226	123	155	149	127	103	–	–	-337	114	-525
Net Income to Common	-144	10	475	486	–	–	–	–	–	–	149	127	103	97	110	-337	114	–
EPS (Basic)(per share)	-2.91	0.20	9.27	9.57	7.77	7.35	5.17	4.72	2.60	3.29	3.21	2.72	2.15	2.03	2.16	-5.38	1.75	-7.80
EPS (Diluted)(per share)	-2.91	0.20	9.22	9.48	7.60	7.20	5.07	4.62	2.54	3.23	3.13	2.66	2.12	2.01	2.14	-5.38	1.74	-7.80
Shares Outstanding (Basic, Weighted)(shares)	50	51	51	51	50	50	49	48	47	47	46	47	48	48	51	63	65	–
Shares Outstanding (Diluted, Weighted)(shares)	50	52	51	51	51	51	50	49	49	48	48	48	48	48	51	63	66	–
EBITDA	428	589	931	955	855	668	549	493	419	364	301	274	248	247	260	-205	260	-365
Provision for Credit Losses	–	–	–	6.71	1.66	6.38	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 27, 2026

Profitability, TTM

Gross margin: –
Operating margin: 2.3%
Net margin: -6.0%
Return on equity, FY2025: -4.4%

Financial strength

Current ratio: 1.35
Debt to equity: 0.92
Debt to assets: 34.9%
Cash to current liabilities: 16.9%

Valuation

P/E ratio: –
Price to sales: 3.60
Price to book: 5.07
Dividend yield: –